55 reports

Erectile Dysfunction Drugs Market Report Overview Erectile Dysfunction Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Erectile Dysfunction Drugs market types and applications. It is a focused study on Erectile Dysfunction Drugs...

  • Dysfunction Drug
  • World
  • Health Provider Density

Drug for Erectile DysfunctionDrug Profile

  • Pharmaceutical
  • Dysfunction Drug
  • World
  • South Africa
  • Sichuan
  • Drug Approval
  • Pharmaceutical Registrations

Exhibit ## Global Erectile Dysfunction Drugs Market by Distribution

  • Dysfunction Drug
  • World
  • Smoking Prevalence
  • Diabetes Prevalence

Drug for Erectile DysfunctionDrug Profile

  • Dysfunction Drug
  • World
  • South Africa
  • Pharmaceutical Registrations
  • Drug Approval

Drug for Erectile DysfunctionDrug Profile

  • Dysfunction Drug
  • World
  • South Africa
  • Pharmaceutical Registrations
  • Drug Approval

Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus. The global drugs for erectile dysfunction market is expected to grow from $3.76 billion in 2020 to $4.99 billion in 2021 at a compound annual growth rate (CAGR) of 32.7%. The growth is mainly...

  • Dysfunction Drug
  • World
  • Europe
  • United Kingdom
  • Chronic Disease Prevalence

Drugs For Erectile Dysfunction Global Market Report 2020-30: Covid 19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global drugs for erectile dysfunction market as it emerges from the Covid 19 shut down. Description: Where is the largest...

  • Dysfunction Drug
  • World

"Erectile Dysfunction - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Erectile Dysfunction. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides...

  • Dysfunction Drug
  • World
  • United States
  • Health Expenditure

The ongoing clinical trial research report- “2019 Erectile Dysfunction Ongoing Clinical Trials Study” analyzes the current scenario of all active Erectile Dysfunction trials across the world. The report presents top level analysis of global Erectile Dysfunction clinical trials across countries, companies and universities. It is designed to...

  • Dysfunction Drug
  • Clinical Trial
  • World
  • APAC

Report Scope: The report focuses on newer shockwave devices and innovations in frequency length, as well as devices that have been recently launched or are in development.This report will also highlight the current and future market potentiality of shockwave therapy, with detailed analysis of competitive environment between...

  • Dysfunction Drug
  • World

About this market The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market’s growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences...

  • Dysfunction Drug
  • World

Female Sexual DysfunctionDrug Profiles

  • Dysfunction Drug
  • World
  • Depression Prevalence
  • Drug Approval

Major companies in the genito-urinary drugs market include Daiichi Sankyo Company; Pfizer Inc; Bayer AG; Astellas Pharma Inc and Allergan Plc. The global genito-urinary drugs market is expected to grow from $49.24 billion in 2020 to $53.78 billion in 2021 at a compound annual growth rate (CAGR) of 9.2%. The growth is mainly due to the...

  • Pharmaceutical
  • Incontinence Product
  • Genitourinary System Disease
  • Dysfunction Drug
  • World
  • Health Expenditure
  • Population Over Age Of 65

Female Sexual DysfunctionDrug Profiles

  • Dysfunction Drug
  • World
  • Depression Prevalence
  • Drug Approval

High levels of pipeline activity are being observed in Left Ventricular Dysfunction treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Armaron Bio Pty Ltd., Bayer AG, Innopharmax Inc., Mesoblast Ltd, Quantum Genomics Corp. and others. A Significant contribution to the Left...

  • Drug Development
  • Therapy
  • Clinical Trial
  • Dysfunction Drug
  • World
  • Drug Approval

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Erectile Dysfunction Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Erectile Dysfunction pipeline products. The Erectile Dysfunction pipeline guide presents complete overview of drugs currently...

  • Dysfunction Drug
  • World

Summary Erectile Dysfunction pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into constipation R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress. Extensive...

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • Dysfunction Drug

The global clinical trial report- “2019 Erectile Dysfunction Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Erectile Dysfunction. It presents in-depth analysis of Erectile Dysfunction clinical trials across markets and companies. The research work is for providing complete understanding into trends...

  • Dysfunction Drug
  • Clinical Trial
  • World

Erectile Dysfunction (ED) Drugs Market - Overview This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market.Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile...

  • Dysfunction Drug
  • World

Global Phosphodiesterase (PDE) inhibitors Market: About this market Phosphodiesterase inhibitors represent a drug class comprising drugs with a similar mechanism of action i.e. by inhibiting PDE enzymes. This phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. Our analysis...

  • Dysfunction Drug
  • Healthcare
  • World
  • Health Expenditure

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Dysfunction Drug
  • World

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Dysfunction Drug
  • World

This study covers the world outlook for erectile dysfunction drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Dysfunction Drug
  • World
  • Gross Domestic Product
  • Disposable Income

This study covers the world outlook for sexual dysfunction drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Dysfunction Drug
  • World
  • Gross Domestic Product
  • Disposable Income

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Dysfunction Drug
  • World

This study covers the world outlook for erectile dysfunction therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Dysfunction Drug
  • World
  • Gross Domestic Product
  • Disposable Income

Erectile Dysfunction ongoing clinical trials report provides comprehensive analysis and trends in global Erectile Dysfunction disease clinical trials. The research work analyzes the ongoing Erectile Dysfunction clinical trial trends across countries and companies. The report focuses on drugs and therapies being evaluated for Erectile...

  • Clinical Trial
  • Dysfunction Drug
  • World

Sexual dysfunction drugs market in Americas

  • Dysfunction Drug
  • APAC
  • Drug Approval
  • Disposable Income

This study covers the latent demand outlook for sexual dysfunction drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its...

  • Dysfunction Drug
  • India
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for sexual dysfunction drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred...

  • Dysfunction Drug
  • China
  • Disposable Income
  • Purchasing Power Parity